189 related articles for article (PubMed ID: 21078948)
21. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
[TBL] [Abstract][Full Text] [Related]
22. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
23. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
Nettles RE; Schürmann D; Zhu L; Stonier M; Huang SP; Chang I; Chien C; Krystal M; Wind-Rotolo M; Ray N; Hanna GJ; Bertz R; Grasela D
J Infect Dis; 2012 Oct; 206(7):1002-11. PubMed ID: 22896665
[TBL] [Abstract][Full Text] [Related]
25. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.
Langley DR; Kimura SR; Sivaprakasam P; Zhou N; Dicker I; McAuliffe B; Wang T; Kadow JF; Meanwell NA; Krystal M
Proteins; 2015 Feb; 83(2):331-50. PubMed ID: 25401969
[TBL] [Abstract][Full Text] [Related]
26. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.
Toma J; Weinheimer SP; Stawiski E; Whitcomb JM; Lewis ST; Petropoulos CJ; Huang W
J Virol; 2011 Apr; 85(8):3872-80. PubMed ID: 21289125
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor.
Martín-García J; Cao W; Varela-Rohena A; Plassmeyer ML; González-Scarano F
Virology; 2006 Mar; 346(1):169-79. PubMed ID: 16309726
[TBL] [Abstract][Full Text] [Related]
28. HIV entry and fusion inhibitors.
Chantry D
Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
[TBL] [Abstract][Full Text] [Related]
29. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
30. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development.
Kadow J; Wang HG; Lin PF
Curr Opin Investig Drugs; 2006 Aug; 7(8):721-6. PubMed ID: 16955683
[TBL] [Abstract][Full Text] [Related]
32. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
[TBL] [Abstract][Full Text] [Related]
33. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
Tilton JC; Amrine-Madsen H; Miamidian JL; Kitrinos KM; Pfaff J; Demarest JF; Ray N; Jeffrey JL; Labranche CC; Doms RW
AIDS Res Hum Retroviruses; 2010 Jan; 26(1):13-24. PubMed ID: 20055594
[TBL] [Abstract][Full Text] [Related]
34. HIV entry inhibitors: mechanisms of action and resistance pathways.
Briz V; Poveda E; Soriano V
J Antimicrob Chemother; 2006 Apr; 57(4):619-27. PubMed ID: 16464888
[TBL] [Abstract][Full Text] [Related]
35. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
Peters PJ; Duenas-Decamp MJ; Sullivan WM; Brown R; Ankghuambom C; Luzuriaga K; Robinson J; Burton DR; Bell J; Simmonds P; Ball J; Clapham PR
Retrovirology; 2008 Jan; 5():5. PubMed ID: 18205925
[TBL] [Abstract][Full Text] [Related]
36. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
[TBL] [Abstract][Full Text] [Related]
37. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.
Melby T; Demasi R; Cammack N; Miralles GD; Greenberg ML
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1366-73. PubMed ID: 18184079
[TBL] [Abstract][Full Text] [Related]
38. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
40. Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.
Zou S; Zhang S; Gaffney A; Ding H; Lu M; Grover JR; Farrell M; Nguyen HT; Zhao C; Anang S; Zhao M; Mohammadi M; Blanchard SC; Abrams C; Madani N; Mothes W; Kappes JC; Smith AB; Sodroski J
J Virol; 2020 May; 94(10):. PubMed ID: 32161177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
